- Home
- RA vs AQST Comparison
RA vs AQST Comparison
Compare RA & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RA | AQST |
|---|---|---|
| Founded | N/A | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 705.0M | 504.0M |
| IPO Year | 2016 | 2007 |
Fundamental Metrics
Financial Performance| Metric | RA | AQST |
|---|---|---|
| Price | $13.12 | $4.16 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 139.9K | ★ 1.4M |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $67,430,000.00 |
| Revenue This Year | N/A | $10.08 |
| Revenue Next Year | N/A | $49.60 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 0.77 |
| 52 Week Low | $12.46 | $2.22 |
| 52 Week High | $13.59 | $7.55 |
Technical Indicators
Market Signals| Indicator | RA | AQST |
|---|---|---|
| Relative Strength Index (RSI) | 56.30 | 51.70 |
| Support Level | $12.87 | $3.70 |
| Resistance Level | $13.30 | $4.42 |
| Average True Range (ATR) | 0.15 | 0.15 |
| MACD | 0.05 | 0.01 |
| Stochastic Oscillator | 86.57 | 60.26 |
Price Performance
Historical ComparisonAbout RA Brookfield Real Assets Income Fund Inc.
Brookfield Real Assets Income Fund Inc. is a diversified, closed-end management investment company. The investment objective of the Fund is to seek high total return, through high current income and secondarily, through growth of capital. The Fund seeks to achieve its investment objective by investing in the real asset class, which includes the following: Real Estate Securities, Infrastructure Securities, and Natural Resources Securities. The Fund operates in a single operating segment.
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.